- Home
- SRV vs INMB Comparison
SRV vs INMB Comparison
Compare SRV & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRV
- INMB
- Stock Information
- Founded
- SRV 2007
- INMB 2015
- Country
- SRV United States
- INMB United States
- Employees
- SRV N/A
- INMB N/A
- Industry
- SRV Finance Companies
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- SRV Finance
- INMB Health Care
- Exchange
- SRV Nasdaq
- INMB Nasdaq
- Market Cap
- SRV 123.3M
- INMB 112.0M
- IPO Year
- SRV N/A
- INMB 2019
- Fundamental
- Price
- SRV $44.12
- INMB $4.48
- Analyst Decision
- SRV
- INMB Strong Buy
- Analyst Count
- SRV 0
- INMB 2
- Target Price
- SRV N/A
- INMB $21.00
- AVG Volume (30 Days)
- SRV 33.9K
- INMB 223.4K
- Earning Date
- SRV 01-01-0001
- INMB 10-31-2024
- Dividend Yield
- SRV 13.38%
- INMB N/A
- EPS Growth
- SRV N/A
- INMB N/A
- EPS
- SRV N/A
- INMB N/A
- Revenue
- SRV N/A
- INMB $42,000.00
- Revenue This Year
- SRV N/A
- INMB N/A
- Revenue Next Year
- SRV N/A
- INMB N/A
- P/E Ratio
- SRV N/A
- INMB N/A
- Revenue Growth
- SRV N/A
- INMB N/A
- 52 Week Low
- SRV $30.73
- INMB $4.32
- 52 Week High
- SRV $44.30
- INMB $14.74
- Technical
- Relative Strength Index (RSI)
- SRV 53.01
- INMB 41.02
- Support Level
- SRV $43.96
- INMB $4.32
- Resistance Level
- SRV $45.26
- INMB $4.87
- Average True Range (ATR)
- SRV 1.06
- INMB 0.33
- MACD
- SRV 0.06
- INMB -0.01
- Stochastic Oscillator
- SRV 85.94
- INMB 11.03
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.